NextCell Pharma AB

As of May 31, 2025, NextCell Pharma AB carries a market capitalization of 120.30M, placing it among publicly traded companies globally. Its enterprise value stands at 103.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

NextCell Pharma AB's next confirmed earnings release is scheduled for October 22, 2026.

As of May 31, 2025, NextCell Pharma AB has 111.39M shares outstanding.

These figures are as of May 31, 2025. The price-to-sales ratio is 7.55, and the price-to-book ratio stands at 2.93.

These figures are as of May 31, 2025. The EV/Sales ratio of 10.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 103.59M versus a market cap of 120.30M, with the gap driven by net debt and cash on the balance sheet.

As of May 31, 2025, NextCell Pharma AB maintains a current ratio of 4.57, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended May 31, 2025, NextCell Pharma AB posted a negative return on equity (ROE) of -90.26, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -70.17, reflecting losses generated across the asset base. The company generates approximately 2.50M in revenue per employee across its workforce of 4.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 21.40 indicates how many times NextCell Pharma AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, NextCell Pharma AB's stock has gained approximately 4.96% over the past 52 weeks. The 50-day moving average sits at 1.06, while the 200-day moving average is 1.16.

Over the twelve months ended May 31, 2025, NextCell Pharma AB generated 9.98M in revenue and converted that into -39.76M in net income, yielding earnings per share of -0.57. EBITDA reached -38.16M, while operating income came in at -40.70M.

These figures are as of May 31, 2025. Total book value stands at 41.09M, with working capital of 24.20M providing operational flexibility.

NextCell Pharma AB produced -36.05M in operating cash flow over the twelve months ended May 31, 2025. After subtracting -2.45M in capital expenditures, free cash flow totaled -38.49M - equivalent to -0.55 per share.

Over the twelve months ended May 31, 2025, NextCell Pharma AB posted a gross margin of -43.23, reflecting its pricing power and cost economics. The operating margin of -407.82 and net profit margin of -398.39 provide insight into operational efficiency.

These figures cover the twelve months ended May 31, 2025. Free cash flow yield is negative at -51.05: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -28.65, meaning NextCell Pharma AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

NextCell Pharma AB's most recent stock split took place on May 28, 2024.

As of May 31, 2025, NextCell Pharma AB has an Altman Z-Score of -0.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.